



**Procter & Gamble Hygiene
and Health Care Limited**
CIN: L24239MH1964PLC012971
Registered Office:
P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91-22) 2826 6000
Fax: (91-22) 2826 7337
Website: in.pg.com

October 30,2023

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Ref:- Scrip Code:- 500459

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Scrip Code:- PGHH

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended September 30, 2023

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 4.25 pm and ended at 4:53 pm), the Unaudited Financial Results for the quarter ended September 30, 2023 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended September 30, 2023;
- b. Press Release; and
- c. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended September 30, 2023 furnished by Statutory Auditors of the Company.

Kindly take the same on record. Thanking you.

For **Procter & Gamble Hygiene and Health Care Limited**

Flavia Machado
Senior Legal Manager- Legal and Secretarial



Procter & Gamble Hygiene
and Health Care Limited
CIN : L24239MH1984PLC012971
Registered Office: P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
(91 – 22) 2826 6000 phone
(91 – 22) 2826 7337 fax
Website: in.pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2023

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)
	Three Months Ended 30th Sept 2023	Preceding Three Months Ended 30th June 2023 (Audited) Refer note 4	Corresponding Three Months Ended 30th Sept 2022	Previous Year Ended 30th June 2023
	(Unaudited)		(Unaudited)	(Audited)
1 Income				
Sale of products	1 13 506	84 874	1 04 092	3 90 521
Other operating revenues	329	379	397	1 269
2 Revenue from operations	1 13 835	85 253	1 04 489	3 91 790
3 Other income	1 577	1 010	673	4 058
Total income (2+3)	1 15 412	86 263	1 05 162	3 95 848
4 Expenses				
a) Cost of raw and packing materials consumed	21 652	19 990	26 630	84 755
b) Purchases of stock-in-trade (Traded goods)	22 285	19 309	21 142	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	574	(3 321)	(4 441)	(853)
d) Employee benefits expense	6 372	4 807	5 126	20 579
e) Finance costs	189	300	95	1 138
f) Depreciation and amortization expense	1 430	1 541	1 396	5 836
g) Advertising & sales promotion expenses	15 347	5 354	15 569	42 652
h) Other expenses	19 116	17 625	19 065	75 393
Total expenses	86 965	65 605	84 582	3 11 901
5 Profit before tax (2+3-4)	28 447	20 658	20 580	83 947
6 Tax expense				
a) Current tax	7 533	5 448	5 415	23 052
b) Deferred tax	(155)	86	(276)	(1 208)
c) Prior year tax adjustments (Refer note 2)	---	---	---	(5 711)
	7 378	5 534	5 139	16 133
7 Profit for the period (5-6)	21 069	15 124	15 441	67 814
8 Other comprehensive income				
Items that will not be reclassified to profit or loss:				
Remeasurement of the defined benefit plans	(250)	(989)	182	(999)
Income tax effect on above	63	248	(46)	251
Total other comprehensive income for the period	(187)	(741)	136	(748)
9 Total comprehensive income for the period (7+8)	20 882	14 383	15 577	67 066
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246
11 Other Equity				91 357
12 Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :				
a) Basic	64.91	46.59	47.57	208.91
b) Diluted	64.91	46.59	47.57	208.91
See accompanying notes to the financial results				

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 30, 2023 and have been subjected to a limited review by the Statutory Auditors of the Company.
- During the previous year ended June 2023, the Company reversed tax provisions amounting to Rs. 5,844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- The figures for the preceding three months ended June 30, 2023 are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2023 and the year to date figures upto the third quarter of that financial year.

For and on behalf of the Board of Directors of
Procter & Gamble Hygiene and Health Care Limited

Vaidyanathan
Viswanathan
Lalgudi

Digitally signed by
Vaidyanathan
Viswanathan Lalgudi
Date: 2023.10.30
16:41:34 +05'30'

Place: Mumbai
Date: October 30, 2023

LV Vaidyanathan
Managing Director



Procter & Gamble Hygiene and Health Care Limited
CIN: L24239MH1964PLC012971
Registered Office:
P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai - 400099
Tel: (91-22) 2826 6000
Fax: (91-22) 2826 7337
Website: in.pg.com

Procter & Gamble Hygiene and Health Care Ltd. announces first quarter results

Sales up 9%, and PAT up 36% for the quarter ended September 30, 2023

Mumbai, October 30, 2023: Procter & Gamble Hygiene and Health Care Ltd. announced today its financial results for the quarter ended September 30, 2023. During the quarter, the Company delivered a strong growth with sales of ₹1138 crore, up 9% versus year ago driven by a superior retail execution and integrated growth strategy. Profit After Tax (PAT) for the quarter was ₹211 crore, up 36% versus year ago led by acceleration of volume growth coupled with product price-mix and productivity.

LV Vaidyanathan, Managing Director, Procter & Gamble Hygiene and Health Care Ltd. shared, "We delivered a strong top and bottom-line growth in the quarter, by executing our integrated strategy of a focused product portfolio of daily use categories where performance drives brand choice, superiority — across product performance, packaging, brand communication, retail execution and consumer and customer value — productivity, constructive disruption, and an agile and accountable organization. Our team's execution of these strategies has enabled us to build momentum in the first quarter, and we are confident that these strategies will help us deliver balanced growth and value creation."

The Company's business continues to grow behind a strong product portfolio, superior consumer communication and a continuous stream of product innovations aimed at delighting consumers, like Whisper Hygiene Comfort, Whisper Choice Nights, Vicks ZzzQuil- World's #1 Sleep Supplement, Vicks Roll-On Inhaler and Vicks Xtra Strong. Whisper also continues to raise awareness about menstrual hygiene education through 'Whisper Menstrual Health & Hygiene Program'.

About Procter & Gamble Hygiene and Health Care Limited

Procter & Gamble Hygiene and Health Care Ltd. (PGHHCL) is one of India's leading FMCG companies that has in its portfolio WHISPER – India's leading Feminine Hygiene brand, and VICKS – India's No.1 Health Care brand and Old Spice. The company has carved a reputation for delivering high quality, value-added products to meet the needs of consumers. PGHHCL is committed to making every day in the lives of Indian consumers better through superior value propositions. Please visit in.pg.com for the latest news.

For details contact: Madison Public Relations:

Malika Bhavnani +91 9820496099; malika.bhavnani@madisonpr.in



**Procter & Gamble Hygiene
and Health Care Limited**
CIN : L24239MH1964PLC012971
Registered Office: P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
(91 – 22) 2826 6000 phone
(91 – 22) 2826 7337 fax
Website: in.pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th SEPTEMBER 2023

Particulars	(₹ in Lakhs)			
	(1) Three Months Ended 30th Sept 2023 (Unaudited)	(2) Preceding Three Months Ended 30th June 2023 (Audited) Refer note 4	(3) Corresponding Three Months Ended 30th Sept 2022 (Unaudited)	(4) Previous Year Ended 30th June 2023 (Audited)
1 Income				
Sale of products	1 13 506	84 874	1 04 092	3 90 521
Other operating revenues	329	379	397	1 269
2 Revenue from operations	1 13 835	85 253	1 04 489	3 91 790
3 Other income	1 577	1 010	673	4 058
Total Income (2+3)	1 15 412	86 263	1 05 162	3 95 848
4 Expenses				
a) Cost of raw and packing materials consumed	21 652	19 980	26 630	84 755
b) Purchases of stock-in-trade (Traded goods)	22 285	19 309	21 142	82 401
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	574	(3 321)	(4 441)	(853)
d) Employee benefits expense	6 372	4 807	5 126	20 579
e) Finance costs	189	300	95	1 138
f) Depreciation and amortization expense	1 430	1 541	1 396	5 836
g) Advertising & sales promotion expenses	15 347	5 354	15 569	42 652
h) Other expenses	19 116	17 625	19 065	75 393
Total expenses	86 965	65 605	84 582	3 11 901
5 Profit before tax (2+3-4)	28 447	20 658	20 580	83 947
6 Tax expense				
a) Current tax	7 533	5 448	5 415	23 052
b) Deferred tax	(155)	86	(276)	(1 208)
c) Prior year tax adjustments (Refer note 2)				(5 711)
7 Profit for the period (5-6)	7 378	5 534	5 139	16 133
8 Other comprehensive income				
Items that will not be reclassified to profit or loss:				
Remeasurement of the defined benefit plans	(250)	(989)	182	(999)
Income tax effect on above	63	(248)	(46)	251
Total other comprehensive income for the period	(187)	(741)	136	(748)
9 Total comprehensive income for the period (7+8)	20 882	14 383	15 577	67 066
10 Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246
11 Other Equity				
a) Basic	64.91	46.59	47.57	208.91
b) Diluted	64.91	46.59	47.57	208.91
See accompanying notes to the financial results				

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 30, 2023 and have been subjected to a limited review by the Statutory Auditors of the Company.
- During the previous year ended June 2023, the Company reversed tax provisions amounting to Rs. 5,844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 - Operating Segments. Accordingly, no separate segment information has been provided.
- The figures for the preceding three months ended June 30, 2023, are the balancing figures between the audited figures in respect of the full financial year ended June 30, 2023 and the year to date figures upto the third quarter of that financial year.

Place: Mumbai
Date: October 30, 2023

**ROSHNI
RAYOMAND
MARFATIA**

**For and on behalf of the Board of Directors of
Procter & Gamble Hygiene and Health Care Limited**

Digitally signed by
Vaidyanathan
Viswanathan
Lalgudi
Date: 2023.10.30
16:41:34 +05'30'

**LV Vaidyanathan
Managing Director**